DMRA

Damora Therapeutics, Inc.

DMRA.US damoratx.com + Research + Basket
ISIN KYG2646Y1044
Employees 7
Phone 781 281 9020
Fiscal year end December
IPO Mar 10, 2026
Address Building 23, Waltham, MA, United States, 02453
22.53
+0.92 (+4.26%)
USD · NASDAQ
52-week range
4.95
38.33
Trading at 53% of the 52-week range
Market Cap
1.36B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
6.25
Div. Yield
N/A
% Institutions
105.83%
% Insiders
8.43%

1 Year

+201.8%

3 Year

+61.3%

10 Year

-94.2%
Description

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Actions

Add an action for DMRA.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Garrett Winslow Esq. Senior VP, General Counsel & Corporate Secretary 1979
Ms. Jennifer A. Jarrett M.B.A. CEO, President & Director 1971
Mr. Ulf J. Nilsson Ph.D. Co-Founder NA
Dr. Hakon Leffler M.D., Ph.D. Co-Founder NA
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. Co-Founder NA
Mr. Brian Burkavage CPA Senior VP of Finance, Principal Financial & Accounting Officer 1983
Mr. Sherwin Sattarzadeh Chief Operating Officer 1979
Dr. Becker Hewes M.D. Chief Medical Officer 1966

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Jan 02, 2026 Hans T Schambye N/A Sale 700.00 $21.38 $14.97K SEC
Jan 02, 2026 Lori Firmani N/A Sale 135.00 $21.41 $2.89K SEC
Jul 03, 2025 Hans T Schambye N/A Sale 735.00 $3.38 $2.48K SEC
Jul 03, 2025 Lori Firmani N/A Sale 147.00 $3.39 $498.33 SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 9.23M Jun 30, 2026 14.96% $0.01 2.07%
venBio Select Advisor LLC 3.78M Jun 30, 2026 6.13% $0.88 0.00%
BlackRock Inc 3.16M Jun 30, 2026 5.12% $0.00 1,321.56%
HHG PLC 2.36M Mar 31, 2026 3.83% $0.03 135,765.21%
Viking Global Investors LP 2.31M Jun 30, 2026 3.74% $0.17 0.00%
Remedium Capital Partners, LLC 2.05M Jun 30, 2026 3.31% $11.78 0.00%
COMMODORE CAPITAL LP 1.94M Jun 30, 2026 3.14% $3.00 0.00%
BRAIDWELL LP 1.62M Jun 30, 2026 2.62% $1.56 81.08%
Bellevue Group AG 1.62M Jun 30, 2026 2.62% $0.89 -29.55%
State Street Corp 1.55M Jun 30, 2026 2.50% $0.00 740.30%
Balyasny Asset Management LLC 1.23M Jun 30, 2026 1.99% $0.04 -15.12%
Perceptive Advisors LLC 1.22M Jun 30, 2026 1.98% $0.48 0.00%
Wellington Management Company LLP 1.06M Jun 30, 2026 1.71% $0.00 0.00%
Geode Capital Management, LLC 965.36K Jun 30, 2026 1.56% $0.00 300.36%
Siren, L.L.C. 900.00K Jun 30, 2026 1.46% $0.47 0.00%
UBS Group AG 840.29K Jun 30, 2026 1.36% $0.00 423.82%
Vestal Point Capital LP 575.00K Jun 30, 2026 0.93% $0.35 -4.17%
Vanguard Portfolio Management, LLC 365.50K Jun 30, 2026 0.59% $0.00 0.00%
Northern Trust Corp 359.71K Jun 30, 2026 0.58% $0.00 825.12%
The Goldman Sachs Group Inc 339.38K Jun 30, 2026 0.55% $0.00 284.19%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Company Fund 1.84M 2.97% ▲ 0.46% Aug 31, 2026
2 iShares Russell 2000 ETF 1.23M 1.99% ▼ 1.14% Sep 30, 2026
3 Fidelity Small Cap Growth 834.04K 1.35% ▲ 0.00% Jul 31, 2026
4 State Street® SPDR® S&P® Biotech ETF 728.45K 1.18% ▼ 1.87% Sep 30, 2026
5 JPMorgan Small Cap Growth A 710.26K 1.15% ▼ 2.87% Aug 31, 2026
6 Fidelity Small Cap Index 583.68K 0.95% ▲ 0.86% Jul 31, 2026
7 Fidelity Growth Company K6 540.25K 0.88% ▲ 0.48% Aug 31, 2026
8 Fidelity Select Health Care 500.00K 0.81% ▲ 0.00% Aug 31, 2026
9 Fidelity Series Growth Company 454.91K 0.74% ▲ 0.46% Aug 31, 2026
10 Fidelity Select Biotechnology 454.56K 0.74% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $1.36B
EBITDA: $-96.33M
Book Value: $6.25
Earnings/Share: $-0.25
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -21.61%
ROE (TTM): -99.74%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $1.47B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 61.74M
Shares Float: 40.89M
% Insiders: 8.43%
% Institutions: 105.83%
Short % Float: 9.74%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-34.00K
Gross Profit
subtotal
$-34.00K
SG&A
adjust
$-9.69M
R&D
adjust
$-201.19M
Operating Income
subtotal
$-210.87M
Other / Non-Operating Items
adjust
$1.03M
Net Income
subtotal
$-209.84M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about DMRA.US!